Effective approved drug therapy for Cryptosporidium in immunocompromised patients 26 does not exist. Here we investigated the non-absorbed antihelminthic drug, pyrvinium pamoate, 27 for growth-inhibition against the intestinal protozoan parasite, Cryptosporidium parvum. Fifty 28 percent growth inhibition in human enterocytic HCT-8 cells by a quantitative alkaline 29 phosphatase immunoassay was 354 nM for pyrvinium. For comparison, in the same assay, fifty 30 percent growth inhibition was 711 µM for paromomycin and 27 µM for chloroquine. We used a 31 neonatal mouse model to measure in vivo anti-Cryptosporidium activity of pyrvinium pamoate. 32
INTRODUCTION
incubation at 37°C for 90 min to induce excystation and allow cell invasion, cells were washed 115 once with warm PBS to remove unexcysted oocysts and free sporozoites. Negative control wells 116 to measure background absorbance received 5 × 10 3 non-viable oocysts subjected to 5 cycles of 117 freezing in liquid nitrogen and thawing in a 37° C water bath. Drugs were diluted to appropriate 118 concentrations and added to cells in 150 µL of parasite growth medium. For pyrvinium 119 treatment, final DMSO levels were 0.5%. Vehicle control wells for the pyrvinium group received 120 growth medium containing 0.5% DMSO. The glycoside antibiotic, paromomycin, and another 121 quinoline, chloroquine, were used as comparison drugs. Each drug concentration was tested in 122 triplicate wells in 2 independent experiments. Plates were incubated for 48 hours at 37°C in a 5% 123 CO 2 /95% humidified air incubator, then fixed in 8% formalin for 2 hours at room temperature. 124
After fixation, plates were washed 3× with PBS, then blocked for 1 hour with 300 µL of a 125 blocking solution consisting of 5% bovine serum albumin (BSA) and 0.002% Tween-20 in PBS. 126
Rat anti-Cryptosporidium polyclonal sera raised to washed sporozoite membrane proteins (29) 127 (provided by Steve Upton at Kansas State University) were diluted 1:500 in a solution of 1% 128 BSA/0.002%Tween-20 in PBS and 50 µL was added to each well. After a 30 min incubation at 129 room temperature, the wells were washed 3× with PBS and 50 µL of goat anti-rat horseradish 130 calculated as 1-(mean A 450 in infected wells with drug / mean A 450 in infected wells without 138 drug) × 100. 139
The cytotoxicity of pyrvinium pamoate to The in vivo efficacy of pyrvinium pamoate was tested using a neonatal mouse model formg/kg/day or 12.5 mg/kg/day for 4 or 6 consecutive days. Five mg/kg/day is the dose of 161 pyrvinium used for treatment of Enterobius in humans. Pyrvinium was initially dissolved in 162 100% DMSO or ethanol. Prior to administration, drug stocks were diluted to the desired 163 concentration in water so that final solvent levels were 5% for DMSO and 5% or 10% for 164 ethanol. Vehicle treated mice received 5% DMSO in water or 5 or 10% ethanol in water. As a 165 positive control comparison drug, paromomycin was administered at 100 mg/kg/day for 4 or 6 166 consecutive days. Vehicle control mice received an equal volume of water. All mice were 167 euthanized by cervical dislocation on day 9 post-infection, when one study showed that levels of 168 oocyst shedding peak in infected neonatal mice (20) . To quantify oocyst shedding, fecal smears 169 were made from 2-3 microliters of stool removed from the distal colon. Thin smears were 170 methanol-fixed and oocysts were stained with immunofluorescent antibodies (IFA) using a 171 The effects of pyrvinium, paromomycin and chloroquine treatment on parasite growth in 206 cell culture were investigated by exposure of infected cells to the antimicrobial agents for 48 207 hours ( Fig. 1) . Fifty percent inhibitory concentrations (IC 50 ) for pyrvinium, paromomycin and 208 chloroquine were calculated as 354 nM, 711 µM and 27 µM, respectively, indicating that 209 pyrvinium was ~2000 times more potent than paromomycin and ~76 times more potent than 210 chloroquine in vitro. Cytotoxic effects of pyrvinium on HCT-8 cells after 48 hours of exposure 211 were minimal (< 15% reduction in cells) at all dose levels except the highest dose, 1.6 µM, 212 where a 40% reduction in cell numbers was observed. Chloroquine cytotoxicity by the Neutral 213
Red assay was 15% reduction in cells at 100 uM, 12% at 80 uM and <5% at all lower doses. 214
Cytotoxicity of paromomycin in HCT-8 cells has been previously described as negligible by 215 Gargala (12) . 216 217 Drug activity in neonatal mice. 218
The efficacy of pyrvinium, in comparison to that of paromomycin, was tested in a 219 neonatal mouse model (20) . Oocyst shedding by C. parvum-infected mice, as one indicator of 220 drug efficacy, was enumerated by IFA on distal colonic fecal smears made at the time of 221 necropsy. The effects of various treatment regimens on oocyst shedding are presented in Table 1 . 222
At the 5mg/kg/day dose, >90% reduction in oocyst shedding was observed in the pyrvinium-223 treated mice compared to the vehicle control mice. Based on the confidence intervals, the level 224 of oocyst shedding in 5 mg/kg/day pyrvinium treated mice was equivalent to that of 100 225 mg/kg/day paromomycin treated mice, though paromomycin was administered at a 20 fold 226 higher dose. Slightly higher levels of oocyst shedding were observed at the 12.5 mg/kg/day 227 pyrvinium dose, which may be associated with drug-induced toxicity, as 3 mice in this treatment 228 group died though there were no deaths in any other group. However, after 4 days of pyrvinium 229 treatment at either dose, there was no significant reduction in mouse weight compared to controls 230 (data not shown). 231
In addition to evaluation of oocyst shedding, levels of C. parvum trophozoites in the 232 intestinal epithelium were enumerated by microscopic evaluation of H&E stained histological 233 sections from treated and untreated mice (Fig. 2) . The comparative effects of treatment with 234 pyrvinium or paromomycin for 6 consecutive days on levels of C. parvum trophozoites in 235 individual intestinal sections are shown in Fig. 3 . Parasite densities tended to be highest at the 236 terminal ileum, adjacent to the appendix. Though parasite densities were generally lower in the 237 appendix than in the ileum, we observed that low numbers of trophozoites could often be found 238 there even when the ileum appeared to be clear of infection, indicating that the appendix could 239 act as a reservoir for Cryptosporidium in the GI tract, from which the ileum could be re-240 populated. Both drugs showed near 90% or greater reduction in the mean number of trophozoites 241 in the terminal ileum, appendix and colon. 242
An overall score for comparing levels of trophozoites in treated versus untreated groups 243 was derived by summing the total number of trophozoites per 1000 cells over all of the tissue 244 sections for each individual mouse. Box plots displaying the differences in this summary score 245 between treatment groups are presented in Fig. 4 . Based on mean summary score values, there 246 was an 85% reduction in trophozoites in the pyrvinium treated group and a 99% reduction in the 247 paromomycin treated group compared to their respective controls. However, the mean summary 248 score for the pyrvinium group was skewed by a single outlier mouse that had levels of 249 trophozoites equivalent to those seen in control mice, though levels of oocyst shedding by this 250 mouse were much lower than seen in controls. The reduction in trophozoites for both pyrvinium 251 In this study we demonstrated that pyrvinium pamoate was a potent inhibitor of C. 268 parvum growth, both in an in vitro cell culture system and in neonatal mice. In C. parvum-269 infected HCT-8 cells, the IC 50 for pyrvinium (354 nM) was ~2000× lower than the observed IC 50 270 for paromomycin and ~76× lower than that of chloroquine. In previous studies, an IC 50 for 271 paromomycin as low as 83 µM has been reported (29), in contrast to the IC 50 of 711 µM reported 272
A C C E P T E D
here, but variability in IC 50 values for paromomycin have been noted in the literature. In one 273 study, paromomycin treatment at 100 µM resulted in only 40% growth inhibition (17) and in 274 another study, a concentration of 500 µM failed to achieve a measurable decrease in C. parvum 275 levels in vitro (3). Concentrations of paromomycin as high as 3200 µM have been needed to 276 achieve >80% reduction in parasite numbers (24). Several in vitro systems for testing the anti-277
Cryptosporidium activity of drugs have been described in the literature, and variations in the 278 different procedures, along with variability in oocyst infectivity and excystation rates, can make 279 comparison of results between laboratories difficult, as is seen with IC 50 results for 280 paromomycin. In contrast to our observations for paromomycin treatment, the in vitro activity of 281 chloroquine against C. parvum in this study was consistent with previous findings where a 20 282 µM dose produced 33% growth inhibition (3). 283
Pyrvinium was also a potent inhibitor of parasite growth in neonatal mice. A dose of 5 284 mg/day was sufficient to reduce oocyst shedding to 4-7% of that seen in controls. This level of 285 reduction was equivalent to that seen for mice treated with 100 mg/kg/day paromomycin, a 20 286 fold higher drug dose. A 2.5 fold increase in the pyrvinium dose failed to further reduce oocyst 287 shedding levels below those seen for the 5 mg/kg group. Unexpectedly, oocyst shedding 288 increased slightly at the 12.5 mg/kg dose, possibly caused by drug-induced diarrhea, which was 289 more severe in this treatment group than at the 5 mg/kg dose. Three deaths provided further 290 evidence of drug toxicity at the 12.5 mg/kg dose, which may have resulted from increased 291 absorption of pyrvinium from the gastrointestinal tract in neonatal mice. Acute oral toxicity 292 studies have shown that higher doses of pyrvinium pamoate are tolerated in adult mice. In one 293 report, doses as high as 125 mg/kg were well tolerated (5). In another study, treatment with 128 294 mg/kg pyrvinium resulted in >50% mortality, though a dose of 64 mg/kg was associated with a 295 93.5% survival rate (25). Results from drug studies in other animals, including rats, dogs and 296 monkeys, demonstrate the relatively low toxicity of more than 100 mg/kg/day of pyrvinium 297
on October 16, 2017 by guest http://aac.asm.org/ Downloaded from pamoate following oral administration (25) and doses as high as 35 mg/kg have been safely used 298 in humans for the treatment of strongyloidiasis (27). However, the observed low dose toxicity of 299 pyrvinium pamoate in neonatal mice prevents dose-escalation studies using this animal model for 300 cryptosporidiosis, which will have to be investigated using an alternative model system such as a 301 piglet diarrhea model (24). 302
Though intensity of oocyst shedding was equivalent for pyrvinium and paromomycin 303 treated groups, the reduction in mean levels of trophozoites in the intestinal epithelium was 304 greater for paromomycin treated mice than for pyrvinium treated mice, compared to their 305 respective controls (99% and 85% reduction, respectively). However, this difference between the 306 two drug treatment groups was not statistically significant. The mean histology score for the 307 pyrvinium group was significantly skewed by a single outlier mouse that had levels of 308 trophozoites in the ileum equivalent to those seen in controls, though levels were reduced in the 309 appendix, cecum and colon. As a result, the mean histology score for this group was ~33× higher 310 than the median value and was associated with very large standard deviations. Surprisingly, the 311 oocyst count from the fecal smear of this outlier mouse was lower than oocyst counts from 312 several other mice in the treatment group. To verify the IFA results, stool remaining in the colon 313 section on the histology slide from the outlier mouse was examined for the presence of oocysts, 314 but no evidence of large numbers of oocysts was seen anywhere in the colon. The reasons for the 315 discrepancy between oocyst shedding levels and the histology results for this mouse are unclear. 316
It is possible that different mechanisms of action are responsible for the effects of pyrvinium on 317 trophozoites and oocyst production. Without a better understanding of the mechanism of 318
Cryptosporidium inhibition by pyrvinium, it is difficult to explain these results. It is also 319 interesting to note that the two littermates of the outlier mouse had the second and third highest 320 numbers of trophozoites in the group, indicating that some shared exposure, such as the nursing 321 habits of the dam, may have affected the response of these mice to drug treatment. One possible 322 explanation is that the dam was providing a sub-optimal amount of milk, which along with drug-323 induced diarrhea, could have contributed to the malnourishment of these mice. The effects of 324 malnourishment on severity of Cryptosporidium infection are well known (19) . 325
The anti-parasitic mechanism of action of pyrvinium has not been studied in depth and 326 consequently is not well understood. The proposed mechanism of action in intestinal helminths 327 has been inhibition of respiration in aerobes or interference with exogenous glucose utilization 328 (8, 22) . Despite mutagenic activity in bacteria and yeast, there has been no evidence of 329 genotoxicity in mammalian cell lines (18) pyrvinium, n=10, (white bars) against it no drug controls, n=9, (black bars) were performed at 506 different times. Control mice had few trophozoites in the proximal ileum, with levels peakingat 507 the terminal ileum and decreasing again to the colon. Oocysts in fecal matter were not counted. (21159, 10, 13750, and 63, for paromomycin no drug control, paromomycin, pyrvinium no drug 519 control and pyrvinium, respectively). A Kruskal-Wallis non-parametric test of equality and 520 pairwise comparisons using a non-parametric two-sample Mann-Whitney test showed that levels 521 of trophozoites in both the pyrvinium and paromomycin treatment groups were significantly 522 (P<0.05) lower than their respective controls, but not significantly different from each other 523 (P=0.2682). 524
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